Q-linea signs first commercial evaluation contract for ASTar

Q-linea AB (publ) (OMX: QLINEA) – Q-linea announces today that the first commercial evaluation contract has been signed for ASTar® with a Swedish regional hospital.

The ASTar Instrument and ASTar BC G- Kit offer the broadest combination of antimicrobials and dilution ranges in a single analysis for Gram-negative bacteria. The test enables the analysis of both fastidious and non-fastidious bacteria, for rapid fully automatic and comprehensive results that support optimal treatment decisions.

“We are delighted to announce that we now have received the first commercial evaluation contract in direct connection with the official launch of ASTar. We are very positive about the future.”, says Jonas Jarvius, CEO at Q-linea.

ASTar Instrument and ASTar BC G- Kit is CE-marked but not FDA 510(k)-cleared and not available for sale in the U.S.

About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company’s lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

Q-linea signs first commercial evaluation contract for ASTar